Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer

B. L. Weber, Charles Vogel, S. Jones, H. Harvey, L. Hutchins, J. Bigley, J. Hohneker

Research output: Contribution to journalArticle

172 Citations (Scopus)

Abstract

Purpose: We evaluated single-agent intravenous (IV) vinorelbine as first- and second-line treatment for advanced breast cancer (ABC) in patients who were not resistant to anthracyclines. Objective tumor response (TR) and toxicity were assessed. Patients and Methods: A total of 107 women were enrolled onto this multicenter, nonrandomized, open-label phase II study. Patients were stratified into first- and second-line treatment groups, based on prior treatment history. Vinorelbine was initially given at 30 mg/m2/wk, with dose modification for toxicity as indicated. Therapy was continued until disease progression or severe toxicity mandated withdrawal or until the patient asked to be removed from the study. Results: The objective response rate for all patients was 34% (95% confidence interval [CI], 25% to 44%): 35% (95% CI, 23% to 48%) for first-line patients and 32% (95% CI, 20% to 47%) for second-line patients. Nine first-line and three second-line patients obtained a complete response (CR). The median duration of objective response was 34 weeks in both groups. The overall survival durations of first- and second- line patients were 67 weeks and 62 weeks, respectively. Granulocytopenia was the predominant dose-limiting toxicity. Two patients died on study as a result of granulocytopenic sepsis. Conclusion: Single-agent vinorelbine is an effective and well-tolerated agent for first- and second-line therapy of ABC. The results of this study confirm the findings of similar international trials and suggest vinorelbine should be considered a valid treatment option for patients with ABC and a potential component in future combination regimens for this disease.

Original languageEnglish
Pages (from-to)2722-2730
Number of pages9
JournalJournal of Clinical Oncology
Volume13
Issue number11
StatePublished - Jan 1 1995
Externally publishedYes

Fingerprint

Breast Neoplasms
Therapeutics
Confidence Intervals
vinorelbine
Agranulocytosis
Anthracyclines
Disease Progression
Sepsis
History
Survival
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Weber, B. L., Vogel, C., Jones, S., Harvey, H., Hutchins, L., Bigley, J., & Hohneker, J. (1995). Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. Journal of Clinical Oncology, 13(11), 2722-2730.

Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. / Weber, B. L.; Vogel, Charles; Jones, S.; Harvey, H.; Hutchins, L.; Bigley, J.; Hohneker, J.

In: Journal of Clinical Oncology, Vol. 13, No. 11, 01.01.1995, p. 2722-2730.

Research output: Contribution to journalArticle

Weber, BL, Vogel, C, Jones, S, Harvey, H, Hutchins, L, Bigley, J & Hohneker, J 1995, 'Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer', Journal of Clinical Oncology, vol. 13, no. 11, pp. 2722-2730.
Weber BL, Vogel C, Jones S, Harvey H, Hutchins L, Bigley J et al. Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. Journal of Clinical Oncology. 1995 Jan 1;13(11):2722-2730.
Weber, B. L. ; Vogel, Charles ; Jones, S. ; Harvey, H. ; Hutchins, L. ; Bigley, J. ; Hohneker, J. / Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. In: Journal of Clinical Oncology. 1995 ; Vol. 13, No. 11. pp. 2722-2730.
@article{73700d51f47f4d748166b3cd6b6266e7,
title = "Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer",
abstract = "Purpose: We evaluated single-agent intravenous (IV) vinorelbine as first- and second-line treatment for advanced breast cancer (ABC) in patients who were not resistant to anthracyclines. Objective tumor response (TR) and toxicity were assessed. Patients and Methods: A total of 107 women were enrolled onto this multicenter, nonrandomized, open-label phase II study. Patients were stratified into first- and second-line treatment groups, based on prior treatment history. Vinorelbine was initially given at 30 mg/m2/wk, with dose modification for toxicity as indicated. Therapy was continued until disease progression or severe toxicity mandated withdrawal or until the patient asked to be removed from the study. Results: The objective response rate for all patients was 34{\%} (95{\%} confidence interval [CI], 25{\%} to 44{\%}): 35{\%} (95{\%} CI, 23{\%} to 48{\%}) for first-line patients and 32{\%} (95{\%} CI, 20{\%} to 47{\%}) for second-line patients. Nine first-line and three second-line patients obtained a complete response (CR). The median duration of objective response was 34 weeks in both groups. The overall survival durations of first- and second- line patients were 67 weeks and 62 weeks, respectively. Granulocytopenia was the predominant dose-limiting toxicity. Two patients died on study as a result of granulocytopenic sepsis. Conclusion: Single-agent vinorelbine is an effective and well-tolerated agent for first- and second-line therapy of ABC. The results of this study confirm the findings of similar international trials and suggest vinorelbine should be considered a valid treatment option for patients with ABC and a potential component in future combination regimens for this disease.",
author = "Weber, {B. L.} and Charles Vogel and S. Jones and H. Harvey and L. Hutchins and J. Bigley and J. Hohneker",
year = "1995",
month = "1",
day = "1",
language = "English",
volume = "13",
pages = "2722--2730",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "11",

}

TY - JOUR

T1 - Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer

AU - Weber, B. L.

AU - Vogel, Charles

AU - Jones, S.

AU - Harvey, H.

AU - Hutchins, L.

AU - Bigley, J.

AU - Hohneker, J.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Purpose: We evaluated single-agent intravenous (IV) vinorelbine as first- and second-line treatment for advanced breast cancer (ABC) in patients who were not resistant to anthracyclines. Objective tumor response (TR) and toxicity were assessed. Patients and Methods: A total of 107 women were enrolled onto this multicenter, nonrandomized, open-label phase II study. Patients were stratified into first- and second-line treatment groups, based on prior treatment history. Vinorelbine was initially given at 30 mg/m2/wk, with dose modification for toxicity as indicated. Therapy was continued until disease progression or severe toxicity mandated withdrawal or until the patient asked to be removed from the study. Results: The objective response rate for all patients was 34% (95% confidence interval [CI], 25% to 44%): 35% (95% CI, 23% to 48%) for first-line patients and 32% (95% CI, 20% to 47%) for second-line patients. Nine first-line and three second-line patients obtained a complete response (CR). The median duration of objective response was 34 weeks in both groups. The overall survival durations of first- and second- line patients were 67 weeks and 62 weeks, respectively. Granulocytopenia was the predominant dose-limiting toxicity. Two patients died on study as a result of granulocytopenic sepsis. Conclusion: Single-agent vinorelbine is an effective and well-tolerated agent for first- and second-line therapy of ABC. The results of this study confirm the findings of similar international trials and suggest vinorelbine should be considered a valid treatment option for patients with ABC and a potential component in future combination regimens for this disease.

AB - Purpose: We evaluated single-agent intravenous (IV) vinorelbine as first- and second-line treatment for advanced breast cancer (ABC) in patients who were not resistant to anthracyclines. Objective tumor response (TR) and toxicity were assessed. Patients and Methods: A total of 107 women were enrolled onto this multicenter, nonrandomized, open-label phase II study. Patients were stratified into first- and second-line treatment groups, based on prior treatment history. Vinorelbine was initially given at 30 mg/m2/wk, with dose modification for toxicity as indicated. Therapy was continued until disease progression or severe toxicity mandated withdrawal or until the patient asked to be removed from the study. Results: The objective response rate for all patients was 34% (95% confidence interval [CI], 25% to 44%): 35% (95% CI, 23% to 48%) for first-line patients and 32% (95% CI, 20% to 47%) for second-line patients. Nine first-line and three second-line patients obtained a complete response (CR). The median duration of objective response was 34 weeks in both groups. The overall survival durations of first- and second- line patients were 67 weeks and 62 weeks, respectively. Granulocytopenia was the predominant dose-limiting toxicity. Two patients died on study as a result of granulocytopenic sepsis. Conclusion: Single-agent vinorelbine is an effective and well-tolerated agent for first- and second-line therapy of ABC. The results of this study confirm the findings of similar international trials and suggest vinorelbine should be considered a valid treatment option for patients with ABC and a potential component in future combination regimens for this disease.

UR - http://www.scopus.com/inward/record.url?scp=0028848191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028848191&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 2722

EP - 2730

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 11

ER -